Repligen elects Martin D. Madaus as Chair, succeeding Tony Hunt effective Mar 13, 2026

REPLIGEN CORP

Tony Hunt retires as Executive Chair and Board member effective March 13, 2026; will serve as advisor through March 2027.
Dr. Martin D. Madaus, a director since February 2023, elected as Chair of the Board effective March 13, 2026.
Madaus brings 36 years of bioprocessing industry experience; formerly Chairman, President and CEO of Millipore.
The succession was previously disclosed in Repligen's June 14, 2024 8-K filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.